Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
187 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Pulmonary Arterial Hypertension - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Pulmonary Arterial Hypertension - Pipeline Review, H2 2014', provides an overview of the Pulmonary Arterial Hypertension's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pulmonary Arterial Hypertension and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pulmonary Arterial Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pulmonary Arterial Hypertension pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Pulmonary Arterial Hypertension Overview 8 Therapeutics Development 9 Pipeline Products for Pulmonary Arterial Hypertension - Overview 9 Pipeline Products for Pulmonary Arterial Hypertension - Comparative Analysis 10 Pulmonary Arterial Hypertension - Therapeutics under Development by Companies 11 Pulmonary Arterial Hypertension - Therapeutics under Investigation by Universities/Institutes 14 Pulmonary Arterial Hypertension - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Pulmonary Arterial Hypertension - Products under Development by Companies 19 Pulmonary Arterial Hypertension - Products under Investigation by Universities/Institutes 22 Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development 23 Actelion Ltd 23 APT Therapeutics, Inc. 24 Arena Pharmaceuticals, Inc. 25 Asahi Kasei Pharma Corp. 26 Bayer AG 27 Bial - Portela & Ca, S.A. 28 Cardioxyl Pharmaceuticals, Inc. 29 Celladon Corporation 30 Celsion Corporation 31 Corridor Pharmaceuticals Inc. 32 Cytokinetics, Inc. 33 Eli Lilly and Company 34 Gilead Sciences, Inc. 35 HanAll Biopharma Co., Ltd. 36 Ironwood Pharmaceuticals, Inc. 37 Lacer, S.A. 38 Longevity Biotech, Inc 39 Mast Therapeutics, Inc. 40 Merck & Co., Inc. 41 Mezzion Pharma Co. Ltd. 42 miRagen Therapeutics, Inc. 43 Nippon Shinyaku Co., Ltd. 44 Novartis AG 45 PharmaIN Corporation 46 PhaseBio Pharmaceuticals, Inc. 47 Pluristem Therapeutics Inc. 48 Proteo, Inc. 49 Reata Pharmaceuticals, Inc. 50 Sagene Pharmaceuticals, Inc. 51 Sinoxa Pharma GmbH 52 Suda Ltd 53 Therametrics holding AG 54 Toray Industries, Inc. 55 United Therapeutics Corporation 56 Pulmonary Arterial Hypertension - Therapeutics Assessment 57 Assessment by Monotherapy Products 57 Assessment by Combination Products 58 Assessment by Target 59 Assessment by Mechanism of Action 62 Assessment by Route of Administration 65 Assessment by Molecule Type 67 Drug Profiles 69 (allopurinol + apocynin) - Drug Profile 69 (chlorthalidone + valsartan) - Drug Profile 70 Antibody for Cancer and PAH - Drug Profile 71 Antibody for Pulmonary Arterial Hypertension - Drug Profile 72 APT-102 - Drug Profile 73 bardoxolone methyl - Drug Profile 75 beraprost sodium LA - Drug Profile 78 BIA-51058 - Drug Profile 81 bosentan - Drug Profile 82 bosentan CR - Drug Profile 84 C-122 - Drug Profile 85 C-301 - Drug Profile 86 DasKloster-1000-01 - Drug Profile 87 Drugs to Modulate Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile 89 Elafin - Drug Profile 90 esuberaprost sodium - Drug Profile 92 fasudil - Drug Profile 93 GS-4997 - Drug Profile 94 imatinib mesylate - Drug Profile 95 IW-1973 - Drug Profile 97 LA-419 - Drug Profile 98 lisuride - Drug Profile 99 macitentan - Drug Profile 101 MK-8892 - Drug Profile 104 Mydicar - Drug Profile 105 nitric oxide - Drug Profile 107 Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile 108 PB-1046 - Drug Profile 109 PB-1120 - Drug Profile 111 Peptide to Modulate Urotensin-II Receptor for PAH - Drug Profile 112 PGC-VIP - Drug Profile 113 PK-10453 - Drug Profile 114 R-190 - Drug Profile 115 ralinepag - Drug Profile 117 riociguat - Drug Profile 118 RNAi Oligonucleotide to Inhibit miR-145 for PAH - Drug Profile 120 selegiline + PDE-5 Inhibitor - Drug Profile 121 selexipag - Drug Profile 122 Small Molecule for Pulmonary Arterial Hypertension - Drug Profile 124 Small Molecule to Antagonize Notch Receptor for Pulmonary Arterial Hypertension and Hypoxia - Drug Profile 125 Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile 126 Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension - Drug Profile 128 Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile 129 Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile 130 sodium nitrite - Drug Profile 131 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 133 SUD-004 - Drug Profile 135 Synthetic Peptide to Agonize VPAC2 for Pulmonary Arterial Hypertension - Drug Profile 136 tadalafil - Drug Profile 137 TXA-127 - Drug Profile 139 udenafil - Drug Profile 141 Pulmonary Arterial Hypertension - Recent Pipeline Updates 143 Pulmonary Arterial Hypertension - Dormant Projects 170 Pulmonary Arterial Hypertension - Discontinued Products 171 Pulmonary Arterial Hypertension - Product Development Milestones 172 Featured News & Press Releases 172 Appendix 182 Methodology 182 Coverage 182 Secondary Research 182 Primary Research 182 Expert Panel Validation 182 Contact Us 183 Disclaimer 183
List of Tables Number of Products under Development for Pulmonary Arterial Hypertension, H2 2014 13 Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H2 2014 14 Number of Products under Development by Companies, H2 2014 16 Number of Products under Investigation by Universities/Institutes, H2 2014 18 Comparative Analysis by Late Stage Development, H2 2014 19 Comparative Analysis by Clinical Stage Development, H2 2014 20 Comparative Analysis by Early Stage Development, H2 2014 21 Comparative Analysis by Unknown Stage Development, H2 2014 22 Products under Development by Companies, H2 2014 23 Products under Development by Companies, H2 2014 (Contd..1) 24 Products under Investigation by Universities/Institutes, H2 2014 26 Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H2 2014 27 Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics, Inc., H2 2014 28 Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H2 2014 29 Pulmonary Arterial Hypertension - Pipeline by Asahi Kasei Pharma Corp., H2 2014 30 Pulmonary Arterial Hypertension - Pipeline by Bayer AG, H2 2014 31 Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca, S.A., H2 2014 32 Pulmonary Arterial Hypertension - Pipeline by Cardioxyl Pharmaceuticals, Inc., H2 2014 33 Pulmonary Arterial Hypertension - Pipeline by Celladon Corporation, H2 2014 34 Pulmonary Arterial Hypertension - Pipeline by Celsion Corporation, H2 2014 35 Pulmonary Arterial Hypertension - Pipeline by Corridor Pharmaceuticals Inc., H2 2014 36 Pulmonary Arterial Hypertension - Pipeline by Cytokinetics, Inc., H2 2014 37 Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H2 2014 38 Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences, Inc., H2 2014 39 Pulmonary Arterial Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 40 Pulmonary Arterial Hypertension - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2014 41 Pulmonary Arterial Hypertension - Pipeline by Lacer, S.A., H2 2014 42 Pulmonary Arterial Hypertension - Pipeline by Longevity Biotech, Inc, H2 2014 43 Pulmonary Arterial Hypertension - Pipeline by Mast Therapeutics, Inc., H2 2014 44 Pulmonary Arterial Hypertension - Pipeline by Merck & Co., Inc., H2 2014 45 Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2014 46 Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics, Inc., H2 2014 47 Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014 48 Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2014 49 Pulmonary Arterial Hypertension - Pipeline by PharmaIN Corporation, H2 2014 50 Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2014 51 Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc., H2 2014 52 Pulmonary Arterial Hypertension - Pipeline by Proteo, Inc., H2 2014 53 Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H2 2014 54 Pulmonary Arterial Hypertension - Pipeline by Sagene Pharmaceuticals, Inc., H2 2014 55 Pulmonary Arterial Hypertension - Pipeline by Sinoxa Pharma GmbH, H2 2014 56 Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H2 2014 57 Pulmonary Arterial Hypertension - Pipeline by Therametrics holding AG, H2 2014 58 Pulmonary Arterial Hypertension - Pipeline by Toray Industries, Inc., H2 2014 59 Pulmonary Arterial Hypertension - Pipeline by United Therapeutics Corporation, H2 2014 60 Assessment by Monotherapy Products, H2 2014 61 Assessment by Combination Products, H2 2014 62 Number of Products by Stage and Target, H2 2014 64 Number of Products by Stage and Mechanism of Action, H2 2014 67 Number of Products by Stage and Route of Administration, H2 2014 70 Number of Products by Stage and Molecule Type, H2 2014 72 Pulmonary Arterial Hypertension Therapeutics - Recent Pipeline Updates, H2 2014 147 Pulmonary Arterial Hypertension - Dormant Projects, H2 2014 174 Pulmonary Arterial Hypertension - Discontinued Products, H2 2014 175
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
